Bicycle Therapeutics plc (BCYC) Tops Q4 EPS by 5c

Bicycle Therapeutics plc (NASDAQ: BCYC) reported Q4 EPS of ($1.01), $0.05 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $3.55 million.

For earnings history and earnings-related data on Bicycle Therapeutics plc (BCYC) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS Upgrades Apollo Tyres (APTY:IN) to Buy
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand